Open label, multi-center, prospective study to investigate the efficacy and safety of osimertinib in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI (APOLLO Study, NCT02972333) | |
Wang, L.; Xing, L.; Cao, L.; Wang, X.; Feng, J.; Shu, Y.; Shi, Y.; Song, Y.; Yu, J. | |
2017 | |
会议名称 | ANNALS OF ONCOLOGY |
会议日期 | 2017-04-01 |
收录类别 | CPCI-S |
URL标识 | 查看原文 |
内容类型 | 会议论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/6365283 |
专题 | 中国医学科学院 北京协和医学院 |
推荐引用方式 GB/T 7714 | Wang, L.,Xing, L.,Cao, L.,et al. Open label, multi-center, prospective study to investigate the efficacy and safety of osimertinib in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI (APOLLO Study, NCT02972333)[C]. 见:ANNALS OF ONCOLOGY. 2017-04-01. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论